Assertio Holdings, Inc. (ASRT) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-08

Key Insights

Assertio agreed with Garda Therapeutics to extend the tender offer deadline from an unspecified earlier date to May 14, 2026, suggesting potential delays or negotiations in the previously announced merger agreement dated May 1, 2026.
The merger involves Garda Therapeutics acquiring Assertio through a subsidiary (Audi Merger Sub, Inc.), indicating a significant corporate restructuring event that could materially impact shareholder value and company operations.
This extension was announced via Regulation FD disclosure, meaning the information is furnished but not filed under Section 18, limiting its legal liability implications but confirming the material nature of the tender offer deadline change.

Want the newest filings?

This analysis covers the filing from 2026-05-08. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-04-29

Assertio Holdings is undergoing a merger with Garda Therapeutics, with the tender offer deadline extended to May 4, 2026, suggesting potential delays or conditions that required negotiated extension from the original timeline.
The merger agreement was originally dated April 8, 2026, and the extension announcement on April 29 indicates the tender offer commencement was delayed by approximately 3 weeks, which may signal regulatory hurdles, financing conditions, or shareholder approval challenges.
This is a Regulation FD disclosure (non-material event notification), meaning the SEC does not consider this extension announcement to be material information requiring standard filing status, suggesting routine merger logistics rather than unexpected complications.

Filed: 2026-04-21

Garda Therapeutics is commencing a tender offer on April 29, 2026, to acquire all outstanding shares of Assertio Holdings, representing a material merger event that will significantly impact shareholder ownership and the company's independence.
The tender offer follows a 20-day 'window-shop' period that expired on April 28, 2026, allowing Assertio to solicit alternative proposals before Garda's formal offer, which is a standard protective mechanism for shareholders in merger transactions.
This 8-K filing provides formal disclosure of the previously announced Merger Agreement dated April 8, 2026, signaling that the transaction is progressing as planned toward completion with institutional approval and regulatory oversight.

Filed: 2026-04-14

Assertio Holdings, Inc. (ASRT) has completed the sale of its INDOCIN®, SPRIX®, SYMPAZAN®, CAMBIA®, ZIPSOR®, and OTREXUP® product franchises to Cosette Pharmaceuticals, Inc. for $35 million in cash with potential for additional deferred milestone payments.
The divestiture of these non-core product franchises aligns with Assertio's strategic focus and allows the company to streamline its operations and concentrate on its key growth initiatives.
The unaudited pro forma financial statements provided with the 8-K filing indicate the potential financial impact of the asset sale on Assertio's balance sheet and income statement.

Filed: 2026-04-09

Assertio Holdings, Inc. (ASRT) has entered into an agreement to be acquired by Garda Therapeutics, Inc. for $18.00 per share in cash plus one contingent value right (CVR) per share.
The merger is subject to customary closing conditions, including a minimum tender of over 50% of ASRT's outstanding shares and a minimum closing net cash balance of $115 million.
The transaction will provide ASRT shareholders with liquidity and an opportunity to receive additional cash payments through the CVR agreement, pending achievement of certain milestones.

Filed: 2026-03-16

Assertio Holdings, Inc. reported its Q4 2025 and full-year 2025 financial results, indicating the company's performance for the period.
The filing does not mention any material agreements, leadership changes, or earnings surprises that would be considered significant news for investors.
Without additional details on the company's financial performance, it is difficult to assess the overall sentiment and significance of this 8-K filing.

Filed: 2026-01-12

Assertio Holdings has regained compliance with Nasdaq's minimum bid price requirement, allowing the company to continue listing on the Nasdaq Capital Market.
The regaining of compliance indicates that Assertio has successfully addressed any previous issues related to its stock price, which is a positive signal for investors.
The 8-K filing provides a timely update on Assertio's compliance status, demonstrating the company's commitment to transparency and adherence to market regulations.

Other reports for Assertio Holdings, Inc.

Quarterly Report Annual Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.